HC Wainwright Has Pessimistic Outlook of RMTI Q1 Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Rockwell Medical in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their prior forecast of ($0.02). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.10) EPS.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The business had revenue of $24.67 million during the quarter, compared to analysts’ expectations of $23.65 million. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%.

Separately, StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Rockwell Medical Price Performance

Shares of RMTI opened at $1.20 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. The company has a 50 day moving average price of $1.78 and a 200-day moving average price of $2.56. Rockwell Medical has a fifty-two week low of $1.18 and a fifty-two week high of $5.15. The stock has a market capitalization of $40.87 million, a PE ratio of -24.00 and a beta of 1.55.

Institutional Trading of Rockwell Medical

Institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Rockwell Medical during the fourth quarter valued at approximately $28,000. Two Sigma Securities LLC acquired a new position in shares of Rockwell Medical during the fourth quarter worth $33,000. Barclays PLC purchased a new stake in shares of Rockwell Medical during the 3rd quarter valued at $90,000. XTX Topco Ltd boosted its position in shares of Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after purchasing an additional 8,922 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Rockwell Medical by 134,397.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 47,074 shares of the company’s stock worth $187,000 after buying an additional 47,039 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.